For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Vyndamax and Tafamidis meglumine represents a genuine breakthrough . These groundbreaking therapies preserve the transthyretin protein, halting its destructive build-up and lessening the bur